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Background: Methylation of the MLH1 promoter region has been suggested to be a major mechanism of gene
inactivation in sporadic microsatellite instability-positive (MSI-H) colorectal cancers (CRCs). Recently, single-nucleotide
polymorphism (SNP) in the MLH1 promoter region (MLH1-93G/A; rs1800734) has been proposed to be associated with
MLH1 promoter methylation, loss of MLH1 protein expression and MSI-H tumors. We examined the association of
MLH1-93G/A and six other SNPs surrounding MLH1-93G/A with the methylation status in 210 consecutive sporadic
CRCs in Japanese patients.
Methods: Methylation of the MLH1 promoter region was evaluated by Na-bisulfite polymerase chain reaction
(PCR)/single-strand conformation polymorphism (SSCP) analysis. The genotype frequencies of SNPs located in the
54-kb region surrounding the MLH1-93G/A SNP were examined by SSCP analysis.
Results: Methylation of the MLH1 promoter region was observed in 28.6% (60/210) of sporadic CRCs. The proportions
of MLH1-93G/A genotypes A/A, A/G and G/G were 26% (n = 54), 51% (n = 108) and 23% (n = 48), respectively, and they
were significantly associated with the methylation status (p = 0.01). There were no significant associations between
genotype frequency of the six other SNPs and methylation status. The A-allele of MLH1-93G/A was more common in
cases with methylation than the G-allele (p = 0.0094), especially in females (p = 0.0067). In logistic regression, the A/A
genotype of the MLH1-93G/A SNP was shown to be the most significant risk factor for methylation of the MLH1
promoter region (odds ratio 2.82, p = 0.003). Furthermore, a haplotype of the A-allele of rs2276807 located −47 kb
upstream from the MLH1-93G/A SNP and the A-allele of MLH1-93G/A SNP was significantly associated with MLH1
promoter methylation.
Conclusions: These results indicate that individuals, and particularly females, carrying the A-allele at the MLH1-93G/A
SNP, especially in association with the A-allele of rs2276807, may harbor an increased risk of methylation of the MLH1
promoter region.
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Microsatellite instability (MSI) is a form of genomic
instability that can be detected as changes in the length
of repetitive microsatellite sequences. MSI occurs in the
majority of tumors from patients with Lynch syndrome
carrying germline mutations in the DNA mismatch
repair (MMR) genes [1]. MSI also occurs in approximately* Correspondence: ksugano@tcc.pref.tochigi.lg.jp
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reproduction in any medium, provided the or15-20% of sporadic colorectal cancers (CRCs) [1,2].
Methylation of the MLH1 promoter region has been
suggested to be a major mechanism of gene inactivation
in sporadic MSI-positive CRCs [3]. Bi-allelic methyla-
tion of the MLH1 promoter region induced transcrip-
tional silencing in cell lines showing MSI and this
epigenetic mechanism of gene inactivation is analogous
to Knudson’s two-hit hypothesis [4,5].
We previously reported that all CpG sites in a 1-kb
region encompassing the MLH1 promoter were methyl-
ated (designated as full methylation) in CRCs showingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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particularly observed in proximal colon cancers in
females older than 70 years old and led to the tran-
scriptional silencing of the MLH1 gene and the MSI-H
phenotype [7]. Methylation of the MLH1 promoter
region was also observed in 20% of MSI-negative
CRCs, although all of these cases displayed partial
methylation (limited to the most upstream region of
the MLH1 promoter); MLH1 protein expression was
maintained in such cases showing partial methylation.
Thus, there is an important correlation between the
methylation status of the MLH1 promoter and the
development of sporadic MSI-positive CRCs.
Single-nucleotide polymorphisms (SNPs) are the most
common type of human genetic variation and occur at
about every 1000 bases in the human genome. Numer-
ous studies are now ongoing to assess their possible
associations with human diseases or phenotypes [8-10].
SNPs in the promoter region have been shown to influ-
ence gene transcription [11]. G/A SNP −93 bp upstream
of the translation start site was identified in the MLH1
gene promoter region [MLH1-93G/A SNP (rs1800734)]
[12]. The MLH1-93G/A SNP has recently been proposed
to have an association with CRCs, ovarian and endomet-
rial cancer [13-16]. In particular, it was shown to be
associated with MLH1 promoter methylation, loss of
MLH1 protein expression and MSI-H tumors [14,16-21].
However, these results are based largely on analyses of
cancers in Caucasian populations. Allelic frequencies of
the MLH1-93G/A SNP differ between Caucasians and
Japanese, and the frequency of the A-allele in Caucasians
(20-23%) is lower than that in Japanese (46%) [12,16,20].
The purpose of this study was to address the associ-
ation between the MLH1-93G/A SNP and methylation
status in the MLH1 promoter region in a series of
sporadic CRCs in a Japanese population. Furthermore,
we also examined the association between six other
SNPs located in the 54-kb region surrounding the
MLH1-93G/A SNP and methylation status in the MLH1
promoter region. We report here that the MLH1-93G/A
SNP was significantly associated with MLH1 promoter
methylation in a Japanese population. Furthermore, a
haplotype comprising the A-allele of rs2276807 and the
A-allele of MLH1-93G/A SNP showed a significant
association with MLH1 promoter methylation. This
haplotype may be associated with an increased risk for
methylation-positive CRCs, especially in females.
Methods
Tissue samples
Tumor tissues and corresponding normal mucosa were
obtained from 210 consecutive CRC patients who
underwent surgery from 1996 through 1998 at Jichi
Medical University Hospital. Genetic analyses werecarried out in the Oncogene Research Unit/Cancer
Prevention Unit, Tochigi Cancer Center Research
Institute. As all samples were derived from archived
tissue samples, they were coded anonymously, prior to
the analysis of methylation status and genotyping of
the vicinity of the MLH1 promoter regions, according
to the Ethical Guidelines for Human Genome/Gene
Analysis Research (Ministry of Education, Culture,
Sports, Science and Technology, Ministry of Health,
Labour and Welfare and Ministry of Economy, Trade
and Industry, March 29, 2001) and the study protocol
was approved by the institutional review board of each
institution. Normal mucosa was obtained from the
surgical margin of the resected specimen before
sampling the tumor tissue to avoid contamination by
tumor cells. Kindred in whom the Lynch syndrome
was suspected were excluded from this study, since
patients with at least one CRC among first-degree rela-
tives were not included. Tumors were staged according
to a modified version of Dukes classification [22]. DNA
was extracted from fresh tumor material by a standard
procedure using proteinase K digestion and subse-
quent phenol-chloroform extraction. Methylation status
and the genotype of the MLH1 promoter region were
also examined in peripheral blood lymphocytes (PBLs)
from 100 anonymous samples obtained from normal
healthy donors over 50 years of age undergoing routine
health checkups.
Analysis of MSI
Genomic DNA was subjected to PCR amplification at
two mononucleotide microsatellite repeat loci, BAT26
and BAT25. The BAT26 locus contains a 26-repeat
adenine tract and is located in intron 5 of the MSH2
gene, whereas the BAT25 locus contains a 25-repeat
thymine tract located in intron 16 of the c-kit oncogene.
Both loci have been shown to be sensitive markers of
MSI, which manifests as alteration in the size of the
respective mononucleotide repeats in tumor DNA. PCR
reactions were performed as described previously [6].
When either BAT26 or BAT25 showed MSI, we examined
7 microsatellite repeat loci, D2S123, D5S346, D17S250,
MSH3, MSH6, TGFBR2 and BAX, according to the
recommendations of the Bethesda guidelines [23].
Tumors were classified as MSI-H when ≥30% of the 9
markers showed MSI. Low-frequency MSI (MSI-L) is
classified as MSI-negative.
Methylation analysis of the MLH1 promoter region
Na-bisulfite PCR/single-strand conformation polymorph-
ism (SSCP) (BiPS) analysis was performed as described
previously [6,24]. With the adenine residue at the initiation
codon numbered as +1 nt, the MLH1 promoter (−755
to +86) was divided into five regions [region A (from −755
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12 CpG sites), C (from −420 to −188, 16 CpG sites), D
(from −286 to −53, 13 CpG sites) and E (from −73 to +86,
13 CpG sites)] and amplified with 5 sets of PCR primers.
Sequences of PCR primers were as reported previously
[6]. Each primer set was designed to anneal to both
methylated and unmethylated DNA sequences and the
amplicons could be separated by SSCP analysis depending
on their methylation status (Figure 1). Amplified DNA
fragments were visualized using SYBR® Gold nucleic
acid gel stain (Cosmo Bio Co., Tokyo, Japan) and
scanned with a Fluorescent Image Analyzer Model
FLA-3000G (Fuji Photo Film Co., Tokyo, Japan). When
the bands showed mobility shifts, they were cut from the
gel, reamplified and directly sequenced using an ABI 310
PRISM™ sequencer (Perkin-Elmer Co., Branchburg, NJ)
with a Big-Dye Terminator Cycle Sequencing Ready
Reaction Kit™ (Perkin-Elmer Co., Branchburg, NJ).
Methylation profiles were classified as follows: full
methylation if all CpG sites in regions A to E showed
methylation, partial methylation if some CpG sites, inFigure 1 BiPS and MSP analysis of MLH1 promoter region. Upper pane
control unmethylated normal DNA; M indicates control methylated DNA. C
band in region A. After SSCP analysis, the extra bands were cut from the e
sequencing procedure. Results of the direct sequencing are shown in the r
dinucleotides in region A are shown. Lower panel: MSP analysis of MLH1 prom
control unmethylated normal DNA; M, control methylated DNA. Tumor tissue (
band in promoter region D. In contrast, tumor tissue (T) from case JM29 (partiaany region, showed methylation, and no methylation if
all CpG sites in any region did not show methylation.
Methylation status of the MLH1 promoter region D
was also analyzed by methylation-specific PCR (MSP)
and the allelic status of methylation was examined by
direct sequencing of the MLH1-93G/A SNP in region
D (Figure 1) [7].Analysis of the genotype frequencies of the MLH1
promoter region
The genotype frequencies of the MLH1-93G/A SNP were
examined by SSCP analysis using an ALFexpress DNA
sequencer (Pharmacia, Tokyo, Japan). Briefly, primer
sequences were 5′Cy5-gacgaagagacccagcaaccc3′ (forward)
and 5′tagatgctcaacggaagtgc 3′ (reverse). The 5′-terminus
of the forward primer was labeled with indodicarbocya-
nine (Cy5) fluorescent dye. PCR reactions were performed
as described previously [7]. The data were analyzed using
the software package Fragment Manager™ (Pharmacia,
Tokyo, Japan).l: BiPS analysis of MLH1 promoter region A is shown. U indicates
ancer tissue (T) from cases JM29 and JM161 displayed a methylated
lectrophoresed gels, reamplified by PCR and sequenced by the dideoxy
ight panel. Sequences (JM161) with methylated cytosines of CpG
oter region D and direct sequencing of the amplified DNA fragments. U,
T) from case JM161 (full methylation case) also showed a methylated
l methylation case) did not show a methylated band in the same region.
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The genotype frequencies of the following six SNPs,
rs2276807 (C/A), rs4678922 (A/T), rs6789043 (T/C),
rs1046512 (C/A), rs3774343 (G/A) and rs4647215 (C/A)
(Figure 2a), located in the 54-kb region surrounding the
MLH1-93G/A SNP, were examined by SSCP analysis.
The locations of the SNPs and the PCR primer se-
quences are described in Additional file 1: Table S1.
Each PCR was carried out using 0.1 μg of genomic DNA
as a template, 10×PCR buffer, 1.25 mM dNTP, 10 μM
each primer and 0.625 units of Taq DNA polymerase in
a total volume of 25 μL. The PCR conditions were as
follows: heat denaturation at 95°C for 12 min, 30 cycles
of PCR comprising 95°C for 30 sec, an annealing step
with different temperatures, namely, 55°C (rs4678922,
rs6789043, rs1046512, rs3774343), 63°C (rs2276807) or
68°C (rs4647215), for 30 sec, and an extension step atFigure 2 Map of six SNPs and EMSA for rs1800734. a. Map of six SNPs,
rs3774343 (G/A) and rs4647215 (C/A), located in the 54-kb region surround
cells. The competition assay was performed with 32P-labeled MLH1-184 to
band was observed in the presence of HeLa nuclear extract, which was blo
The competition assay was performed with matched sets of DNA oligomer
9–11). When a 32P-labeled MLH-93G probe was mixed with nuclear extract f
of MLH1-93G, but not MLH1-A (lanes 5–7). When 32P-labeled MLH-93A probe
not detected (lanes 9–11).72°C for 30 sec, followed by a final extension at 72°C for
10 min. Conditions of the SSCP analysis are described in
Additional file 1: Table S1. The data were analyzed using
the software package Fragment Manager™ (Pharmacia,
Tokyo, Japan).
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using the Gelshift™ Kit (Active
Motif, Carlsbad, CA) (Figure 2b). The sequences of
32P-labeled complementary oligonucleotide pairs and
complementary competitor oligonucleotide pairs cor-
responding to the MLH1 promoter sequence were as
follows: MLH-184 to −132: 5′-ACCCACAGAGTTGA
GAAATTTGACTGGCATTCAAGCTGTCCAATCAATA
GCTG-3′ [12], MLH1-93G: 5′-AGCTACAGCTGAAGG
AAGAA-3′, and MLH1-93A: 5′-AGCTACAGCTAAAGG
AAGAA-3′. After the reaction mixtures with and withoutrs2276807 (C/A), rs4678922 (A/T), rs6789043 (T/C), rs1046512 (C/A),
ing the MLH1-93G/A SNP. b. EMSA using nuclear extracts from HeLa
−132 and unlabeled MLH1-184 to −132 oligomer (lanes 1–3). A shifted
cked in the presence of excess unlabeled competitor (lanes 2 and 3).
s homologous to each genotype of the MLH1-93G/A SNP (lanes 5–7,
rom HeLa cells, a shifted band was blocked by the competitor oligomer
was mixed with the nuclear extract from HeLa cells, a shifted band was
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extract (HeLa Nuclear Extract™; Activemotif, Carlsbad,
CA) were incubated for 20 min on ice, 32P-labeled oligo-
nucleotides were added as a probe. The binding reactions
were carried out according to the manufacturer’s instruc-
tion manual. After the binding reaction, the DNA protein
complexes were resolved by electrophoresis in a 5%
non-denaturing acrylamide gel chilled at 4°C using a
circulating water bath. After electrophoresis, the gel was
dried and scanned with a Fluorescent Image Analyzer
Model FLA-3000G (Fuji Photo Film Co., Tokyo, Japan).
Statistical analysis
Statistical analysis was carried out using Pearson’s chi-
square (Χ2) test or Student’s t-test. Multivariate logistic
regression analysis was performed using Stat View 5.0
statistical package (SAS Institute Inc., Cary, NC) to iden-
tify independent variables associated with the presence
of MLH1 promoter methylation. The included variables
were MLH1-93G/A genotype (A/A vs. A/G +G/G), tumor
location (right vs. left), gender (female vs. male) and age at
onset (more than 70 vs. less than 70). Absence of depart-
ure from the Hardy-Weinberg equilibrium was calculatedTable 1 Association between clinicopathological features and
region in sporadic colorectal cancers
Methylation-positive
Full methylation Partial methylation p values3
Numbers of cases 13 47
Age at onset 72.8 ± 10.6 64.5 ± 10.1 0.012
Gender
Male 3 25 NS(0.054)
Female 10 22
Tumor location1
Right 13 15 <0.0001
Left 0 32
Histological type2





A/B 1/10 2/27 NS
C/D 1/1 14/4
Tumor size (mm) 66.4 ± 35.5 58.2 ± 26.9 NS
MSI-H 13 2 <0.0001
1right: cecum, ascending colon and transverse colon, left: descending colon, sigmoi
2well: well-differentiated adenocarcinoma, mod: moderately differentiated adenoca
mucinous adenocarcinoma.
3P values were analyzed using Pearson’s chi-square test or Student’s t-test between
significant. P values of <0.05 were statistically significant.
4P values were analyzed using Pearson’s chi-square test or Student’s t-test between
methylation-negative cases. NS: not significant. P values of <0.05 were statistically sby the asymptotic Χ2 goodness of fit test. The haplotypes
of the seven SNPs were analyzed using SNPAlyze software
ver. 5.0 (Dynacom, Chiba, Japan) and a case–control
study was performed to examine the relationship between
methylation-positive and methylation-negative subjects.
Permutation analysis was used to determine the empirical
significance and to calculate the probability (p) values
based on 10,000 replications. The global p-values repre-
sent the overall significance using the Χ2-test when the
observed versus expected frequencies of all haplotypes are
considered together.
The individual haplotypes were tested for association
by grouping all other haplotypes together and applying
the Χ2-test with one degree of freedom. P-values <0.05
were considered statistically significant.
Results
Comparison of clinicopathological and molecular features
with methylation status of the MLH1 promoter region
The clinicopathological background, MSI status and the
association of these variables with methylation status are
summarized in Table 1. The category of methylation-
positive includes both full methylation (n = 13) and partialMSI status and methylation status of the MLH1 promoter
Methylation-negative p values4
Total (Full + Partial methylation) (No methylation)
60 150











60.0 ± 28.9 52.2 ± 22.4 0.04
15 4 <0.0001
d colon and rectum.
rcinoma, por: poorly differentiated adenocarcinoma, muc:
cases with full methylation and cases with partial methylation. NS: not
methylation-positive cases (full methylation + partial methylation) and
ignificant.
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between methylation-positive (n = 60) and -negative groups
(n = 150) with respect to gender, tumor location, histologic
type and tumor size (Table 1). Methylation-positive tumors
showed a marked preponderance in females (p = 0.007)
and the proximal colon (p = 0.004). The proportion of
well-differentiated adenocarcinomas was lower in the
methylation-positive group (p = 0.04). The average tumor
size was significantly larger in methylation-positive tumors
(60.0 ± 28.9 mm) than in methylation-negative ones
(52.2 ± 22.4 mm) (p = 0.04). Regarding MSI status, the
frequency of MSI-H was significantly higher in the
methylation-positive group (p < 0.0001).
In the methylation-positive group, there were signifi-
cant differences between patients showing full methyla-
tion (n = 13) and partial methylation (n = 47) with regard
to age at onset, tumor location and MSI status. The
average age at onset was significantly higher in patients
with full methylation than in those with partial methyla-
tion (72.8 ± 10.6 y/o vs. 64.5 ± 10.1 y/o, p = 0.012). All
tumors with full methylation developed in the proximal
colon and showed MSI-H (13/13, 100%), while those
with partial methylation were more prevalent in the
distal colon (32/47, 68.1%) and MSI-H was observed lessTable 2 Association between methylation status of the MLH1
in sporadic colorectal cancers
<Total cases> Genotype
A/A (n = 54) A/G (n = 108) G/G (
Methylation-positive 24 26
Full methylation 4 8
Partial methylation 20 18
Methylation-negative 30 82
(No methylation)
<Female cases> Genotype Allelic frequency
A/A (n = 23) A/G (n = 37) G/G
Methylation-positive 14 13
Full methylation 4 5
Partial methylation 10 8
Methylation-negative 9 24
(No methylation)
<Male cases> Genotype Allelic frequency
A/A (n = 31) A/G (n = 71) G/G
Methylation-positive 10 13
Full methylation 0 3
Partial methylation 10 10
Methylation-negative 21 58
(No methylation)
1P values were analyzed using Pearson’s chi-square test between methylation-posit
significant. P values of <0.05 were statistically significant.
2P values were analyzed using Pearson’s chi-square test between full, partial and m
<0.05 were statistically significant.frequently than in those with full methylation (2/47,
4.3% vs. 13/13, 100%, p < 0.0001).Comparison of MLH1 genotypes with methylation status
of the MLH1 promoter region
Genotypes and allelic frequencies of the MLH1-93G/A
SNP were examined in 210 sporadic CRC patients and
100 PBL samples from normal donors, and the results
were compared with previous studies carried out in co-
horts of different populations. The allelic frequency for
each allele was nearly 50% in the normal donors, other
Japanese and Korean cohorts, while the frequency of the
G-allele (78–80%) was higher than that of the A-allele
(20–22%) in Caucasians [12,16,20,25]. In each study, ob-
served genotype frequencies were consistent with the ex-
pected frequencies according to the Hardy-Weinberg
equilibrium.
In the 210 sporadic CRCs, the proportions of geno-
types A/A, A/G and G/G were 26% (n = 54), 51% (n =
108) and 23% (n = 48), respectively (Table 2). There were
no significant associations between genotypes and clini-
copathological parameters such as age at onset, sex,
tumor location, Dukes classification and histologic type.promoter region and genotypes of the MLH1-93G/A SNP
Allelic frequency
n = 48) p values A G RR p values
10 0.01031 74 46 1.303 0.00941
1 24 10
9 0.02292 58 36 0.00442
38 142 158
(n = 22) p values A G RR p values
5 0.02591 41 23 1.525 0.00671
1 13 7
4 NS2 28 16 0.02232
17 42 58
(n = 26) p values A G RR p values
5 NS1 33 23 1.179 NS1
0 3 3
5 NS2) 30 20 NS2)
21 100 100
ive (full + partial) and methylation-negative cases (no methylation). NS: not
ethylation-negative cases (no methylation). NS: not significant. P values of
Table 3 Multivariate-adjusted odds ratio for MLH1
promoter methylation with genotypes and other variables
Factors OR1 95% CI2 p values3
Genotype of the MLH1
(A/A vs. A/G, G/G)
2.82 1.42-5.62 0.003
Tumor location (right vs. left) 2.40 1.23-4.70 0.011
Gender (female vs. male) 2.06 1.08-3.92 0.027
Age of onset (more than 70 vs.
less than 70)
1.05 0.53-2.07 0.885
1OR: Odds ratio, Odds ratio adjusted for other variables listed in the table.
2CI: Confidence interval.
3P values of <0.05 were statistically significant.
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with methylation-positive and methylation-negative cases
or cases of full methylation, partial methylation and no
methylation of the MLH1 promoter region (Table 2),
and were significantly associated with methylation status
(methylation-positive vs. methylation-negative, p = 0.0103;
full methylation vs. partial methylation vs. no methylation,
p = 0.0229). Allelic frequencies of the MLH1-93G/A SNP
were also compared with methylation status of the MLH1
promoter region. The A-allele was more common in
methylation-positive cases (RR 1.303, p = 0.0094) and was
also more common in subjects with full methylation and
partial methylation than the G-allele (p = 0.0044). In an
analysis of cases subdivided by gender, the proportions of
the MLH1 genotypes were significantly associated with
methylation status in females (methylation-positive vs.
methylation-negative, p = 0.0259), but not in males.
Furthermore, allelic frequencies of the A-allele were
also significantly associated with methylation status in
females (RR 1.525, p = 0.0067).
The clinical characteristics, pathological features and
MSI status based on methylation status (full, partial or
none) were compared according to three genotypes of the
MLH1-93G/A SNP (Additional file 1: Table S2). Patients
who had tumors with full methylation were older and
included a marked preponderance of females (compared
to no methylation), right-sided lesions and MSI-H com-
pared to those with partial and no methylation in geno-
type A/A. In contrast, patients who had tumors with
full methylation were significantly different regarding
tumor location, pathological type (compared to no
methylation) and MSI status compared to those with
partial and no methylation in genotype A/G. The distri-
bution of mucinous and poorly differentiated adenocar-
cinomas is significantly higher in patients with full
methylation compared to those with no methylation. In
genotype G/G, there was no difference among the three
methylation types except for MSI-H.MLH1 genotypes and other risk factors contributing to
MLH1 promoter methylation in CRCs
In logistic regression analysis using the genotype of the
MLH1-93G/A SNP (A/A vs. A/G +G/G), tumor location
(right vs. left), gender (female vs. male) and age at onset
(more than 70 vs. less than 70) as the independent vari-
ables, genotype was shown to be the most significant
risk factor for hypermethylation of the MLH1 promoter
region (Table 3). The odds ratio (OR) in a multivariate
analysis for genotype A/A was 2.82 (95% CI 1.42–5.62,
p = 0.003), followed by tumor location (OR 2.4, 95% CI
1.23–4.70, p = 0.011) and gender (OR 2.13, 95% CI 1.08–
3.92, p = 0.027), while age at onset was not a significant
factor contributing to methylation status.Analysis of genotype frequencies and haplotype of the
SNPs surrounding the MLH1-93G/A SNP and their association
with methylation status
We analyzed the genotype frequencies of six SNPs
located −47 kb upstream to 6.4 kb downstream of the
MLH1 translation start site, namely, rs2276807, rs4678922,
rs6789043, rs1046512, rs3774343 and rs4647215, sur-
rounding the MLH1-93G/A SNP (rs1800734) (Figure 2a),
and their association with MLH1 methylation status
(methylation-positive vs. methylation-negative). The ob-
served frequency of each genotype was consistent with the
expected frequency according to the Hardy-Weinberg
equilibrium. There were no significant associations be-
tween the frequency of each genotype and the methylation
status in these SNPs, except for rs1800734. Furthermore,
we analyzed the haplotypes of these seven SNPs and
their association with MLH1 methylation status (methy-
lation-positive vs. methylation-negative). As a result, only
the haplotype A-A-T-A-A-A-C (rs2276807-rs4678922-
rs6789043-rs1046512-rs1800734-rs3774343-rs4647215)
had a significant association with MLH1 promoter hyper-
methylation in the analysis of all cases (p = 0.012), as well
as in the female cases (p = 0.00038), but this was not
significant in the male cases (Table 4).
EMSA
To elucidate whether the genotype of the MLH1-93G/A
SNP affects the binding activity of nuclear transcription
factors, each synthetic double-stranded DNA oligomer of
theMLH1-93G/A SNP was subjected to EMSA (Figure 2b).
First, in order to confirm the accuracy of this assay,
a competition assay was performed using 32P-labeled
MLH-184 to −132 and unlabeled MLH1-184 to −132
oligomers as described previously [12] (Figure 2b, lanes
1–3). A shifted band was observed with HeLa nuclear
extract, which was blocked completely in the presence
of an excess of unlabeled competitor sequence, as
reported previously. HeLa cell nuclear extract was then
incubated with 20-bp DNA oligomers homologous to
each genotype of the MLH1-93G/A SNP (Figure 2b,
lanes 4–7, 8–11). When the 32P-labeled MLH1-93G
Table 4 Association between haplotype of seven SNPs including MLH1-93G/A SNP and the methylation status of the
MLH1 promoter region
<Total cases > Haplotype1 Haplotype frequencies2 χ2-value p-value3
Total M-negative M-positive
C-A-T-A-A-A-C 0.3141 0.3031 0.3431 0.6274 0.4283
A-A-T-A-G-A-C 0.3116 0.3366 0.2499 2.9665 0.085
A-A-T-A-A-A-C 0.198 0.1667 0.2755 6.3116 0.012
C-T-C-C-G-G-A 0.149 0.1644 0.1102 1.9578 0.1618
C-A-T-A-G-A-C 0.0273 0.0291 0.0213 0.1968 0.6573
<Female cases > Haplotype1) Haplotype frequencies2 χ2-value p-value3
Total M-negative M-positive
C-A-T-A-A-A-C 0.2983 0.3046 0.2955 0.0154 0.9014
A-A-T-A-G-A-C 0.2801 0.3346 0.2017 3.3986 0.0653
A-A-T-A-A-A-C 0.2077 0.1154 0.3452 12.6416 0.00038
C-T-C-C-G-G-A 0.1829 0.21 0.1406 1.2578 0.2621
C-A-T-A-G-A-C 0.0309 0.0354 0.017 0.4818 0.4876
<Male cases > Haplotype1 Haplotype frequencies2 χ2-value p-value3
Total M-negative M-positive
C-A-T-A-A-A-C 0.3323 0.3381 0.3105 0.1457 0.7027
A-A-T-A-G-A-C 0.3243 0.3028 0.4031 1.9442 0.1632
A-A-T-A-A-A-C 0.1916 0.1922 0.1895 2.00E-03 0.9643
C-T-C-C-G-G-A 0.127 0.1414 0.0741 1.7339 0.1879
C-A-T-A-G-A-C 0.0249 0.0255 0.0229 0.0117 0.9138
1Loci of SNPs examined were as follows: rs2276807 - rs4678922 - rs6789043 -rs1046512- rs1800734 (bold letter) - rs3774343 - rs4647215.
2Total cases, methylation-negative (M-negative) cases and methylation-positive (M-positive) cases of haplotype frequencies.
3P values of <0.05 were statistically significant.
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shifted band, which was blocked by the unlabeled
MLH1-93G competitor (Figure 2b, lanes 5 and 6), but
not by the unlabeled MLH1-93A competitor (Figure 2b,
lane 7). However, a shifted band was not detected when
32P-labeled MLH1-93A probe was mixed with the HeLa
cell nuclear extract (Figure 2b, lanes 9–11).
Discussion
Methylation of the MLH1 promoter region and subse-
quent transcriptional silencing have been shown to play a
critical role in the development of MSI-positive CRCs [3].
In a previous study, we reported two types of methylation
profile in the MLH1 promoter region, namely, full methy-
lation and partial methylation [6]. Only the former was
associated with MLH1 gene silencing followed by the
MSI-H phenotype. Partial methylation was observed in
CRCs that developed in both proximal and distal colon,
while the majority of cases showing full methylation devel-
oped in the former. The average age at onset was 10 years
earlier in CRCs with partial methylation than in cases with
full methylation [7]. Partial methylation of the MLH1 pro-
moter region implies initiation of the methylation process,but only a subset of cases with partial methylation may
eventually progress to full methylation and develop MSI-
positive CRCs. It is therefore important to elucidate fac-
tors contributing to methylation of the MLH1 promoter
region in CRC tumorigenesis.
Recent studies have reported such a factor. The
MLH1-93G/A SNP located in the promoter region is
significantly associated with MLH1 promoter methyla-
tion followed by loss of MLH1 protein expression and
plays an important role in MSI-H colorectal tumorigen-
esis [14,16-21]. However, these results are derived mostly
from Caucasian populations, in which the frequencies of
the A-allele and A/A homozygosity are low, at 20–22%
and 4–5%, compared with those in East Asians including
the Japanese [12,16,20,25]. The allelic frequency of
MLH1-93A in a Japanese cohort is as much as 50%;
therefore, study on the Japanese would be important to
validate the results previously reported for Caucasians.
The present study confirms the association between the
genotype of MLH1-93G/A and methylation status for
sporadic CRCs in a Japanese population. The frequency
of methylation of the MLH1 promoter region in CRCs
is significantly higher in those carrying the A-allele in
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with the methylation status of the MLH1 promoter
region, with either full or partial methylation.
Previous studies reported a different affinity of the DNA
binding proteins to theMLH1-93G/A SNP, suggesting that
some transcription factors bind preferentially to the
sequence of MLH1-93G but not to MLH1-93A [26,27].
In EMSA using HeLa cell nuclear extract, the band
showing a mobility shift of the 32P-labeled MLH1-93G
probe had greater intensity than that of the MLH1-93A
probe, suggesting that the affinity of DNA binding
proteins to the MLH1-93A sequence is less than that to
MLH1-93G (Figure 2b). These results suggest that indi-
viduals carrying the MLH1-93A allele are prone to
transcriptional silencing due to the decreased affinity
to allele-specific DNA binding proteins. However, the
definitive mechanism of developing MLH1 promoter
methylation based on the different affinity of DNA
binding proteins to the MLH1-93G/A SNP has not
been elucidated yet. Furthermore, the frequencies of
MSI-positive CRC were reported to be as high as 10–15%
in Caucasians, compared with 9.05% (19/210) in this series
and 13% in another Japanese cohort [28]. Assuming that
the frequency of MSI in the Japanese is the same as that in
Caucasians, carrying the A-allele at the MLH1-93G/A
SNP is not the only risk factor for developing MSI-
positive CRCs. Methylation of the MLH1 promoter region
was found in 28.6% (60/210) of patients and 78.3% (47/60)
showed partial methylation, among which methylation
was limited to the most upstream region of the MLH1
promoter sequences that is distant from the MLH1-93G/
A SNP. As shown in Table 2, the frequency of A/A homo-
zygosity was significantly higher in cases with partial
methylation (42.5%, 20/47) than in those with full
methylation (30.8%, 4/13) or no methylation (20.0%,
30/150) (p = 0.0229). These data suggest that the MLH1-
93G/A genotype was not the only determinant of the
MSI phenotype, which was mostly associated with full
methylation.
We further examined the association between the
genotypes of the six other SNPs surrounding the MLH1-
93G/A SNP (rs1800734) and methylation status in the
MLH1 promoter region. Rs1800734 was the only SNP
showing a significant association with methylation. A
haplotype-based case–control study showed a significant
association of the haplotype comprising A-A-T-A-A-A-
C alleles with MLH1 promoter methylation (Table 4).
The A allele of rs1800734 had only 2 haplotypes com-
prising either C-A-T-A-A-A-C or A-A-T-A-A-A-C, and
the latter showed a significant association with MLH1
promoter hypermethylation; that is, rs2276807 located in
the most upstream region spanning −47 kb of rs1800734
was a determinant of the haplotype associated with MLH1
promoter hypermethylation. These findings suggest thatadditional genetic and/or environmental factors may
contribute to the progression of methylation status from
partial to full methylation, eventually associated with
the MSI phenotype. To our knowledge, this is the first
report of an association between this haplotype and
methylation status in the MLH1 promoter region.
In an analysis of cases subdivided by gender, the fre-
quency of the A-allele MLH1-93G/A SNP was signifi-
cantly higher in females (RR 1.525, p = 0.0067), while this
was not significant in males (RR 1.179) (Table 2). Subjects
carrying the A-allele, particularly females, may harbor an
increased risk of methylation of the MLH1 promoter
region. Furthermore, a haplotype associated with A-alleles
of both rs2276807 and MLH1-93G/A (rs1800734) also
had a significant association with MLH1 promoter methy-
lation in female subjects (Table 4). Slattery et al. suggested
that estrogen exposure in women protects against MSI,
whereas the lack of estrogen in older women increases the
risk of MSI, as shown in a population-based case–control
study [29]. In this series, the clinical characteristics of
methylation-positive tumors, such as female predom-
inance and late age at onset, are compatible with this
epidemiological observation for MSI-positive tumors.
Individuals carrying the A-allele of MLH1-93G/A
(rs1800734), especially in association with the A-allele
of rs2276807, may be susceptible to methylation, but
hormonal status or other genetic factors may modify
the age of onset of the cancer. As the present study size
is relatively small, further studies are needed to eluci-
date the mechanism of methylation susceptibility of
the MLH1 promoter region defined by the genotype of
MLH1-93G/A SNP, along with the relevant haplotype.
Conclusions
The MLH1-93G/A SNP (rs1800734) was significantly
associated with methylation of the MLH1 promoter
region in a Japanese population. Furthermore, a haplotype
comprising the A-allele of rs2276807 and the A-allele of
MLH1-93G/A SNP showed a significant association with
methylation of the MLH1 promoter region. Individuals,
particularly females, carrying the A-allele at the MLH1-
93G/A SNP, especially in association with the A-allele of
rs2276807, may harbor an increased risk of methylation of
the MLH1 promoter region.
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